Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vistagen Therapeutics, Inc.

Vistagen Announces Pricing of $100 Million Underwritten Offering
From Vistagen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
From Vistagen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
From Vistagen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
From Vistagen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
From Vistagen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen to Participate at William Blair Biotech Focus Conference 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen to Participate in Upcoming June Investor Conferences
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
From VistaGen Therapeutics, Inc.
Via Business Wire
VistaGen Appoints Reid Adler as Chief Legal Officer
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
Tickers VTGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.